Table 1.
The Baseline Features of the 23 ET Patients with CVST
| Variable | Value* |
|---|---|
| Demographics | |
| Median age (years, IQR) | 34 (25–50) |
| Male/female | 9 (39.13)/14 (60.87) |
| Duration of CVST (days, IQR) | 182 (20–365) |
| Type of onset | |
| Acute | 12 (52.17) |
| Sub-acute | 4 (17.39) |
| Chronic | 7 (30.43) |
| CVST as initial feature | 19 (82.61) |
| Clinical manifestation | |
| Headache | 23 (100) |
| Nausea/vomiting | 13 (56.52) |
| Blurred vision | 11 (47.83) |
| Seizure | 6 (26.09) |
| Tinnitus | 4 (17.39) |
| Conscious disturbance | 4 (17. 39) |
| Limb weakness | 4 (17. 39) |
| Dysarthria | 3 (13.04) |
| Visual loss | 3 (13.04) |
| Dizziness | 3 (13.04) |
| Neck pain | 2 (8.69) |
| Amaurosis fugax | 1 (4.35) |
| Metamorphopsia | 1 (4.35) |
| Impaired cognition | 1 (4.35) |
| Mental abnormalities | 1 (4.35) |
| Unilateral sensory disturbance | 1 (4.35) |
| Hearing loss | 1 (4.35) |
| Number of sinuses involved | |
| One sinus | 0 |
| More than one sinus | 23 (100) |
| Involved sinuses/veins | |
| Sigmoid sinuses | 20 (86.96) |
| Transverse sinuses | 19 (82.61) |
| Superior sagittal sinus | 18 (78.26) |
| Internal jugular vein | 6 (26.09) |
| Straight sinus | 5 (21.74) |
| Cortical veins | 3 (13.04) |
| Confluence of sinuses | 3 (13.04) |
| Inferior sagittal sinus | 1 (4.35) |
| Parenchymal lesions | |
| No lesion | 10 (43.48) |
| Cerebral infarction | 4 (17.39) |
| Hemorrhagic cerebral venous infarction | 4 (17.39) |
| Cerebral venous infarction | 4 (17.39) |
| Intracranial hemorrhage | 2 (8.69) |
| Intracranial hypertension | 20 (86.96) |
| Papilledema | 19 (82.61) |
| Treatment | |
| Subcutaneous heparin | 18 (78.26) |
| Oral anticoagulant | 23 (100) |
| Antiplatelet | 17 (73.91) |
| Hydroxyurea | 14 (60.87) |
| IFN‑α | 6 (26.09) |
| Outcome at 6 months | |
| Good | 22 (95.6) |
| Poor | 1 (4.34) |
Note: *Values are the number (percentage) unless otherwise indicated.
Abbreviations: ET, essential thrombocythemia; CVST, cerebral venous sinus thrombosis; IQR, interquartile range.